Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 2
2009 2
2010 3
2012 2
2013 1
2014 4
2015 6
2016 2
2017 4
2018 1
2019 3
2020 2
2021 3
2022 10
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome.
Rodriguez-Marquez P, Calleja-Cervantes ME, Serrano G, Oliver-Caldes A, Palacios-Berraquero ML, Martin-Mallo A, Calviño C, Español-Rego M, Ceballos C, Lozano T, San Martin-Uriz P, Vilas-Zornoza A, Rodriguez-Diaz S, Martinez-Turrillas R, Jauregui P, Alignani D, Viguria MC, Redondo M, Pascal M, Martin-Antonio B, Juan M, Urbano-Ispizua A, Rodriguez-Otero P, Alfonso-Pierola A, Paiva B, Lasarte JJ, Inoges S, Lopez-Diaz de Cerio A, San-Miguel J, Fernandez de Larrea C, Hernaez M, Rodriguez-Madoz JR, Prosper F. Rodriguez-Marquez P, et al. Among authors: rodriguez madoz jr. Sci Adv. 2022 Sep 30;8(39):eabo0514. doi: 10.1126/sciadv.abo0514. Epub 2022 Sep 30. Sci Adv. 2022. PMID: 36179026 Free PMC article.
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi.
Cavazza A, Hendel A, Bak RO, Rio P, Güell M, Lainšček D, Arechavala-Gomeza V, Peng L, Hapil FZ, Harvey J, Ortega FG, Gonzalez-Martinez C, Lederer CW, Mikkelsen K, Gasiunas G, Kalter N, Gonçalves MAFV, Petersen J, Garanto A, Montoliu L, Maresca M, Seemann SE, Gorodkin J, Mazini L, Sanchez R, Rodriguez-Madoz JR, Maldonado-Pérez N, Laura T, Schmueck-Henneresse M, Maccalli C, Grünewald J, Carmona G, Kachamakova-Trojanowska N, Miccio A, Martin F, Turchiano G, Cathomen T, Luo Y, Tsai SQ, Benabdellah K; COST Action CA21113. Cavazza A, et al. Among authors: rodriguez madoz jr. Mol Ther Nucleic Acids. 2023 Oct 29;34:102066. doi: 10.1016/j.omtn.2023.102066. eCollection 2023 Dec 12. Mol Ther Nucleic Acids. 2023. PMID: 38034032 Free PMC article. Review.
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
Calviño C, Ceballos C, Alfonso A, Jauregui P, Calleja-Cervantes ME, San Martin-Uriz P, Rodriguez-Marquez P, Martin-Mallo A, Iglesias E, Abizanda G, Rodriguez-Diaz S, Martinez-Turrillas R, Illarramendi J, Viguria MC, Redondo M, Rifon J, Villar S, Lasarte JJ, Inoges S, Lopez-Diaz de Cerio A, Hernaez M, Prosper F, Rodriguez-Madoz JR. Calviño C, et al. Among authors: rodriguez madoz jr. Front Immunol. 2023 Sep 19;14:1270843. doi: 10.3389/fimmu.2023.1270843. eCollection 2023. Front Immunol. 2023. PMID: 37795087 Free PMC article.
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Guedan S, et al. Among authors: rodriguez madoz jr. J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. J Immunother Cancer. 2022. PMID: 35577501 Free PMC article. Review.
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
Martín-Otal C, Lasarte-Cia A, Serrano D, Casares N, Conde E, Navarro F, Sánchez-Moreno I, Gorraiz M, Sarrión P, Calvo A, De Andrea CE, Echeveste J, Vilas A, Rodriguez-Madoz JR, San Miguel J, Prosper F, Hervas-Stubbs S, Lasarte JJ, Lozano T. Martín-Otal C, et al. Among authors: rodriguez madoz jr. J Immunother Cancer. 2022 Aug;10(8):e004479. doi: 10.1136/jitc-2021-004479. J Immunother Cancer. 2022. PMID: 35918123 Free PMC article.
Revealing cell populations catching the early stages of human embryo development in naive pluripotent stem cell cultures.
Moya-Jódar M, Ullate-Agote A, Barlabé P, Rodríguez-Madoz JR, Abizanda G, Barreda C, Carvajal-Vergara X, Vilas-Zornoza A, Romero JP, Garate L, Agirre X, Coppiello G, Prósper F, Aranguren XL. Moya-Jódar M, et al. Among authors: rodriguez madoz jr. Stem Cell Reports. 2023 Jan 10;18(1):64-80. doi: 10.1016/j.stemcr.2022.11.015. Epub 2022 Dec 22. Stem Cell Reports. 2023. PMID: 36563688 Free PMC article.
Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias.
Moya-Garzon MD, Gomez-Vidal JA, Alejo-Armijo A, Altarejos J, Rodriguez-Madoz JR, Fernandes MX, Salido E, Salido S, Diaz-Gavilan M. Moya-Garzon MD, et al. Among authors: rodriguez madoz jr. J Pers Med. 2021 Jan 27;11(2):74. doi: 10.3390/jpm11020074. J Pers Med. 2021. PMID: 33513899 Free PMC article. Review.
One-Step In Vitro Generation of ETV2-Null Pig Embryos.
Moya-Jódar M, Coppiello G, Rodríguez-Madoz JR, Abizanda G, Barlabé P, Vilas-Zornoza A, Ullate-Agote A, Luongo C, Rodríguez-Tobón E, Navarro-Serna S, París-Oller E, Oficialdegui M, Carvajal-Vergara X, Ordovás L, Prósper F, García-Vázquez FA, Aranguren XL. Moya-Jódar M, et al. Among authors: rodriguez madoz jr. Animals (Basel). 2022 Jul 18;12(14):1829. doi: 10.3390/ani12141829. Animals (Basel). 2022. PMID: 35883376 Free PMC article.
SimiC enables the inference of complex gene regulatory dynamics across cell phenotypes.
Peng J, Serrano G, Traniello IM, Calleja-Cervantes ME, Chembazhi UV, Bangru S, Ezponda T, Rodriguez-Madoz JR, Kalsotra A, Prosper F, Ochoa I, Hernaez M. Peng J, et al. Among authors: rodriguez madoz jr. Commun Biol. 2022 Apr 12;5(1):351. doi: 10.1038/s42003-022-03319-7. Commun Biol. 2022. PMID: 35414121 Free PMC article.
In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria.
Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, Rodriguez-Madoz JR. Martinez-Turrillas R, et al. Among authors: rodriguez madoz jr. Mol Ther Methods Clin Dev. 2022 Mar 16;25:137-146. doi: 10.1016/j.omtm.2022.03.006. eCollection 2022 Jun 9. Mol Ther Methods Clin Dev. 2022. PMID: 35402636 Free PMC article.
43 results